Editor,

We wish to highlight an important potential ophthalmic paraneoplastic presentation, that should trigger further investigations to diagnose underlying malignancy.

Paraneoplastic disorders are conditions related to systemic malignancy, but the effects occur at a site remote from the original tumour or metastases.[@b1] It is estimated that paraneoplastic syndromes affecting the nervous or visual systems occur in about 0.01% of patients with cancer[@b2]. A systematic review in 2013 by Rahimy and Saraf listed the 23 cases of paraneoplastic vitelliform maculopathy (PVM) reported in the literature at that time. Most of the cases described were associated with cutaneous or choroidal melanoma and only rarely with carcinoma. All the cases in the review were either associated with metastatic disease at the time of presentation to ophthalmology or metastases were discovered within the following months[@b3]. The average age of onset was 59 years, with equal sex distribution[@b3].

We present two cases of PVM; one associated with underlying cutaneous melanoma and one with primary breast carcinoma.

The first case was a 68-year-old lady ([Figure 1](#f01){ref-type="fig"}) who presented with a one-year history of gradually decreasing vision bilaterally. She had a background of grade III ductal breast carcinoma, diagnosed five years previously. This was treated with mastectomy, chemotherapy and radiotherapy. At presentation her vision was RE 6/12, LE 6/15.

![ ](umj-87-03-199a-g001){#f01}

The second case was a 48-year-old lady who presented with bilateral visual distortion and gradually increasing blurred vision over 1 year. She had a medical history of malignant melanoma diagnosed 4 years before and treated with surgical resection and chemotherapy. At presentation to the ophthalmic team her vision was 6/6 right eye, 6/12 left eye. On retinal examination both cases revealed multifocal yellow-orange vitelliform lesions.

Prompt recognition of the clinical appearance of PVM can facilitate early investigation of underlying malignancy and metastases and it must be remembered that PVM may be the presentation of a distant primary malignancy. In the first case described here, there is currently no evidence of underlying metastases; this patient remains under close monitoring. Unfortunately, there is evidence that PVM is a poor prognostic indicator, with most patients having metastatic disease diagnosed shortly after presentation and succumbing to this from months to four years after presentation with PVM[@b3].
